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Summary: Adherence to once- and twice-daily DAA therapy was high but reduced among 
those on twice-daily therapy. Despite risk factors for non-adherence (stimulant injecting, 
unstable housing, later treatment time), non-adherence did not significantly affect treatment 
outcomes suggesting considerable forgiveness to non-adherence. 
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Abstract 
Background: This study investigated treatment adherence and associated factors among 
people with recent injecting drug use or current opioid agonist therapy (OAT) and compared 
once-daily to twice-daily DAA therapy.  
 
Methods: SIMPLIFY and D3FEAT are international, multicentre studies which recruited 
participants with recent injecting drug use (previous six months; SIMPLIFY, D3FEAT) or 
current OAT (D3FEAT) between March 2016 and February 2017 in eight countries. 
Participants received sofosbuvir/velpatasvir (once-daily; SIMPLIFY) or 
paritaprevir/ritonavir/ombitasvir, dasabuvir (twice-daily) ±ribavirin (D3FEAT) for 12 weeks 
administered in electronic blister-packs. We evaluated overall adherence (proportion of 
prescribed doses taken) and non-adherence (<90% adherent) with comparisons between 
dosing patterns.  
 
Results: Of 190 participants who commenced treatment, 184 (97%) completed treatment. 
Median adherence was 92% with higher adherence among those receiving once-daily vs. 
twice-daily therapy (94% vs. 87%, P=0.005). Overall, 40% of participants (n=76) were 
considered non-adherent (<90% adherent). Recent stimulant injecting (odds ratio [OR] 2.48, 
95% confidence interval [CI] 1.28-4.82), unstable housing (OR 2.18, 95% CI 1.01-4.70), and 
receiving twice-daily dosing (OR 2.81, 95% CI 1.47-5.36) were associated with non-
adherence. Adherence decreased over the course of therapy SVR was high in non-adherent 
(89%) and adherent populations (95%, P=0.174) with no difference in SVR between those 
who did and did not miss at least seven consecutive doses (92% vs 93%, P=0.897). 
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Conclusion: This study demonstrated high adherence to once- and twice-daily HCV DAA 
therapy among people with recent injecting drug use or were currently receiving OAT. The 
levels of non-adherence described did not impact treatment outcomes, suggesting forgiveness 
to non-adherence.  
Keywords: HCV, treatment, PWID, drug use, injecting drug users, adherence, OAT 
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Introduction 
Although direct-acting antiviral (DAA) therapy is effective among people who inject drugs 
(PWID) [1], little is known about adherence, including factors associated with non-adherence 
and the impact of adherence on sustained virologic response (SVR). In many settings, there 
remains resistance among some clinicians to provide HCV treatment for PWID on the basis 
that poor adherence may compromise treatment outcomes [2-4]. 
 
Studies from the interferon-era have demonstrated that treatment completion and adherence 
are comparable between people with and without recent injecting drug use [5, 6]. In the DAA 
era, a small number of studies have demonstrated high adherence to DAA therapy among 
people with recent injecting drug use [6-8] and people receiving opioid agonist therapy 
(OAT) [9-12]. The majority of studies evaluating adherence among people receiving OAT or 
people with recent injecting drug use have used imprecise methods for measuring adherence, 
have heterogenous definitions of recent injecting drug use, are often single-centre, and are 
limited by small sample sizes. No study has compared once-daily and twice-daily DAA 
therapy.  
 
SIMPLIFY and D3FEAT are two international, multicentre phase-4 trials of HCV DAA 
treatment that used electronic blister packs to assess adherence among people with recent 
(last six months) injecting drug use or currently receiving OAT [13, 14]. The aims of this 
analysis were to evaluate adherence to DAA therapy and associated factors and to compare 
adherence between those receiving once-daily and twice-daily therapy.  
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Methods 
Study design and participants 
In two international, multicentre, open-label phase 4 trials (SIMPLIFY and D3FEAT), 
participants were enrolled at 25 sites in Australia (seven sites), Canada (six sites), France 
(two sites), New Zealand (two sites), Norway (two sites), Switzerland (four sites), the United 
Kingdom (one site), and the United States (one site) (SIMPLIFY, ClinicalTrials.gov: 
NCT02336139; and D3FEAT, ClinicalTrials.gov: NCT02498015). These sites included four 
drug and alcohol clinics, one private practice, 17 hospital clinics, and three community 
clinics.  
 
Participants were 18 years of age or older, had chronic HCV genotypes 1-6, were HCV 
treatment-naïve, and had injected drugs in the last six months (self-reported at enrolment; 
SIMPLIFY and D3FEAT) or were currently receiving OAT (D3FEAT; Figure 1). 
Participants with HIV or decompensated liver disease were excluded. All participants 
provided written informed consent before study procedures started.  
 
Procedures 
The study design of the SIMPLIFY and D3FEAT studies have previously been reported [13, 
14]. In SIMPLIFY, patients received one co-formulated sofosbuvir/velpatasvir tablet once-
daily for 12 weeks. In D3FEAT, patients with HCV genotype 1a received two co-formulated 
paritaprevir/ritonavir/ombitasvir tablets once-daily, and one dasabuvir tablet twice-daily for 
12 weeks. Participants with genotype 1a also received weight-based ribavirin twice-daily.  
 
Participants in D3FEAT received ribavirin in pill bottles. All other study drugs were dosed 
weekly in electronic blister packs (Information Mediary Corporation, Ottawa, Canada) that 
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recorded the date and time each dose was removed. In SIMPLIFY, the blister packs contained 
one tablet per day in a single blister. In D3FEAT, the blister packs contained three tablets in 
individual blisters for the morning dose and one tablet in a single blister for the evening dose 
(Figure 2). Participants received AUS$10 (or equivalent) to return each blister pack. 
Adherence was also measured by counting remaining pills in the returned blister packs 
(clinical pill count) and through four-weekly self-reported adherence questionnaires. 
 
Participants completed a self-administered questionnaire on a tablet computer at enrolment, at 
treatment commencement and every fourth week during treatment. The questionnaires 
collected information on demographics, drug and alcohol use, and injecting risk behaviours. 
Stable housing was defined as living in a rented or privately-owned house or flat with all 
other housing categories defined as unstable housing. Hazardous alcohol consumption was 
evaluated using the AUDIT-C [15]. 
 
Outcomes 
The primary endpoint for this analysis was non-adherence to DAA therapy, defined as 
receiving the correct dosing on fewer than 90% of the intended days of treatment as measured 
by electronic blister pack. Correct dosing was at least one dose (one tablet) per day in 
SIMPLIFY and at least two doses (four tablets) per day in D3FEAT. Ribavirin dosing was 
not included in analyses. Where more than the expected number of doses was removed in one 
day adherence was recorded as 100% for the day. In the case of damaged blister packs (n=7) 
or participants removing pills without breaking the senor grid (n=2), clinical pill count was 
used.  
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Overall adherence was a secondary endpoint, calculated by dividing the number of doses 
removed from the blister pack (to a maximum of one per day in SIMPLIFY and two per day 
in D3FEAT) by the number of expected doses (84 doses in SIMPLIFY and 168 for 
D3FEAT). Weekly adherence was calculated assuming all pills removed in a week were 
taken correctly to a maximum of 100% adherence in each week. Overall weekly adherence 
was calculated as the mean of the adherence for each treatment week. Self-reported 
adherence to therapy was calculated by dividing the number of pills taken by the expected 
number of pills.  
 
Statistical analysis 
Participants with <90% (non-adherence) and ≥90% adherence were compared using 
Pearson’s chi-square test. Logistic regression was used to assess predictors of non-adherence. 
Hypothesised predictors included age (stratified by median), sex, education, hazardous 
alcohol consumption, current OAT, past month injecting drug use (any, heroin, cocaine, 
amphetamine, stimulant [cocaine or amphetamine]), frequency of injecting drug use, and 
region of residence (North America, Australia/New Zealand, or Europe). All variables with 
p<0.20 in the unadjusted analyses were considered for multivariate logistic regression models 
using a backward stepwise approach. 
 
The impact of time on treatment was assessed using generalised estimating equation (GEE) 
analyses by including day of treatment as a factor in the model adjusted for age, sex, current 
OAT, heroin injecting, stimulant injecting, unstable housing, and hazardous alcohol 
consumption. As dosing pattern (once- vs twice-daily dosing) was determined to be a 
potential effect modifier, GEE analyses were done stratified by dosing pattern.  
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Statistically significant differences were assessed at p<0.05; p values are two-sided. All 
analyses were performed using the statistical package Stata v14.1 (College Station, TX, 
United States).  
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Results 
Baseline characteristics 
190 participants initiated DAA therapy (SIMPLIFY n=103, D3FEAT n=87). The baseline 
behavioural and demographic characteristics are shown in Table 1. The median age was 48 
years, 74% were male, and 49% reported a high school education or greater. 
 
At baseline, participants included those who had injected drugs in the last six months and 
were not on OAT (33%, n=63), those with injecting in the last six months on OAT (47%, 
n=90), and those without injecting in the last six months on OAT (19%, n=37; D3FEAT only; 
Figure 1). Sixty-one percent (n=115) had injected drugs in the last month. The drugs most 
commonly injected in the month prior to commencement of therapy were heroin (44%) and 
amphetamines (24%; Table 1). In the D3FEAT study, 90% (n=78) were receiving ribavirin. 
 
Differences between those receiving once- (SIMPLIFY) compared to twice-daily (D3FEAT) 
therapy are presented in Table 1. Participants receiving twice-daily therapy were more likely 
to be receiving OAT at baseline and less likely to have injected any drugs in the last month or 
be residing outside Australia/New Zealand. Among people with injecting drug use in the past 
month, there was no significant difference in injecting frequency, or the types of drugs 
injected between those receiving once- or twice-daily therapy. The only difference between 
participants who reported injecting in the last six months at enrolment (SIMPLIFY and 
D3FEAT) and those who did not (D3FEAT) was region of residence with participants with 
current injecting were more likely to reside in Europe (Supplementary Table 1). 
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Treatment completion and adherence 
184 (97%) of 190 participants completed treatment as defined by attending the end of 
treatment study visit (Table 2). Reasons for not completing treatment were loss to follow-up 
(n=3), incarceration (n=1), physician-directed discontinuation (n=1), and death due to 
overdose (n=1). 
 
Overall adherence as measured by blister pack, was 92% (interquartile range [IQR], 81-98%; 
Table 2 and Figure 3) and was higher among those receiving once-daily compared to twice-
daily therapy (94% vs 87%, p=0.005; Figure 4).  Adherence was higher when measured by 
self-report (99% [IQR, 97-100%]) and weekly-assessed blister pack adherence (98% [IQR 
94-100%]). Patient-reported reasons for non-adherence by blister pack assessment were 
available in 175 instances over the course of therapy and included “forgot” (n=104, 59%), 
“inaccessible at time of dose” (n=31, 18%), “side effects” (n=17, 10%), “lost” (n=10, 6%), 
and “other” (n=13, 7%).  
 
By daily blister pack measurement, 90% (n=171) of participants did not take all prescribed 
doses on at least one day of treatment and 48% of participants did not all prescribed doses on 
between one and eight days. Episodes of non-adherence lasted for no more than one 
consecutive day in 42% of participants. Twenty-five participants (13%) had an episode of 
non-adherence for ≥7 consecutive days. 
 
Baseline predictors of non-adherence 
The proportion of participants with <90% blister pack adherence (non-adherence) stratified 
by key behavioural and demographic characteristics is shown in Table 3. In adjusted 
analyses, factors independently associated with non-adherence included unstable housing 
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(aOR 2.18, 95% CI 1.01-4.70), stimulant injecting (last month; aOR 2.48, 95% CI 1.28-4.82), 
and twice-daily dosing (aOR 2.81, 95% CI 1.47-5.36).  
 
In a sensitivity analysis excluding participants from D3FEAT who did not report injecting in 
the last six months at enrolment, factors independently associated with non-adherence 
included stimulant injecting (last month; aOR 2.32, 95% CI 1.16-4.65) and twice-daily 
dosing (aOR 3.26, 95% CI 1.57-6.79; Supplementary Table 2). 
 
Change in adherence over the course of therapy 
The change in adherence over the course of therapy stratified by dosing pattern is shown in 
Figure 5. In GEE analyses, later treatment period was associated with increased odds of non-
adherence (per week; aOR 1.08, 95% CI 1.06-1.09). When models were stratified by 
prescribed dosing pattern, this effect remained for both once-daily dosing (per week; aOR 
1.08, 95% CI 1.06-1.11) and twice-daily dosing (per week; aOR 1.08, 95% CI 1.06-1.10). 
 
Impact of DAA adherence on SVR 
SVR by intent-to-treat was 93% (176 of 190). Among participants who did not achieve SVR, 
the reasons for not achieving SVR included virologic failure (n=3), reinfection (n=1), loss to 
follow-up on treatment (n=6), lost to follow-up following treatment (n=2), and death (n=2). 
All three participants with virologic failure were receiving twice-daily 
paritaprevir/ritonavir/ombitasvir, dasabuvir (individual daily blister pack adherence was 99%, 
98% and 86%).  
 
SVR was lower among those not adherent to therapy, although not significant (89% vs 95%, 
p=0.174) and similar when those who were lost to follow-up were excluded (99% vs 97% 
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p=0.579). There was no difference in SVR among those with and without any missed doses 
(92% vs 95%, P=0.711) or among those who did and did not miss at least seven consecutive 
doses (92% vs 93%, P=0.897). Of the 25 participants with an episode of non-adherence for at 
least seven consecutive days, 21 (84%) completed treatment with no virologic failures. 
Eleven participants had an overall adherence of less than 50%, among whom six achieved 
SVR with no virologic failures. The remaining five participants were lost to follow-up. 
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Discussion 
This study evaluated adherence to HCV DAA therapy and associated factors and compared 
adherence between those receiving sofosbuvir/velpatasvir (once-daily) and 
paritaprevir/ritonavir/ombitasvir, dasabuvir with or without ribavirin (twice-daily) therapy in 
people with injecting drug use in the last six months or receiving OAT. High adherence to 
therapy was observed, although adherence declined during treatment. Adherence was lower 
among people receiving twice-daily therapy. Unstable housing, stimulant injecting, and 
receiving twice-daily therapy were associated with non-adherence. Adherence, missed doses 
during therapy, and extended non-adherent episodes (≥seven days) did not impact SVR, 
suggesting forgiveness to non-adherence with these two regimens. These data are important 
to inform clinical guidelines, clinical management, and health policy, particularly in settings 
where restrictions for the reimbursement of DAA therapy for PWID are in place.  
 
The high median adherence (92%) observed in this study is consistent with other studies 
among people with recent injecting drug use and people receiving OAT [7, 8, 16-21]. 
Previous studies have been limited by their adherence assessment methodologies (self-report 
or clinical pill count) and by small sample sizes. In this study, adherence to once-daily was 
higher compared to twice-daily therapy (94% vs 87%). This finding is novel in the context of 
HCV DAA therapy, consistent with studies of HIV therapy demonstrating higher adherence 
to once-daily regimens [22-25]. These data highlight the importance of simplified dosing to 
optimize adherence among PWID and people receiving OAT. 
 
A decline in adherence was observed during treatment, consistent with previous studies [19, 
21]. The use of electronic blister packs for adherence monitoring was a major strength of this 
study, allowing for detailed and accurate adherence measurement over time, providing a more 
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precise estimate of the effect of time on non-adherence. It is interesting that similar declines 
in adherence were observed irrespective of dosing pattern (once-daily vs. twice-daily). While 
there has been an interest in exploring shorter durations of DAA therapy, it is not clear 
whether there would be a similar ‘forgiveness’ to non-adherence with shorter durations of 
therapy. Further research is needed to evaluate the impact of non-adherence on SVR in the 
context of short-duration DAA therapy.  
 
In addition to dosing pattern, recent stimulant injecting and unstable housing were associated 
with non-adherence. Although studies have demonstrated that recent injecting drug use is 
associated with reduced adherence, most studies have lacked the power to evaluate the effect 
of specific types of drugs on adherence [5, 6, 19, 21]. The association between stimulant use 
and adherence may be of concern given the increasing prevalence of stimulant use reported in 
many countries globally [26]. Unstable housing was also independently associated with non-
adherence. While homelessness has been shown to be associated with treatment failure [27] 
our finding of an association between unstable housing and non-adherence is novel and 
consistent with a systematic review demonstrating poorer adherence to HIV therapy among 
unstably housed populations [28]. Despite these factors impacting adherence, there was no 
significant impact on treatment outcome.  
 
The limited impact of adherence on SVR was an encouraging finding. Among those who did 
not achieve an SVR, the primary reason for treatment failure was loss to follow-up during or 
following treatment. Of the three people who completed therapy and had virologic failure, 
adherence was high (99%, 98% and 86%). Among those with adherence below 50% (n=11), 
six achieved SVR with no recorded virologic failures. This included successful therapy 
among a participant with adherence of only 25%. Despite the observed non-adherence and 
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risk factors for non-adherence, these data highlight that the two HCV DAA regimens 
examined in this study have a considerable degree of forgiveness to non-adherence and 
support the inclusion this population in HCV treatment programs. 
 
This study had some limitations. Although the method of adherence monitoring was precise,  
the blister packs required accurate and correct usage. For example, when more than the 
expected number of pills were removed on a given day, adherence was restricted to 100%. If 
the additional pills removed were taken correctly on subsequent days, then the adherence 
recorded would underestimate the participant’s true adherence. Alternatively, weekly 
adherence, which assumes all pills removed in a given week were taken correctly, likely 
overestimates a participant’s true adherence. Therefore, a participant’s true adherence likely 
lies somewhere between daily- and weekly-assessed blister pack adherence. Despite these 
concerns, blister pack measurement of adherence remains a more robust method of measuring 
adherence compared to clinical pill count or self-report [29].  
 
Another limitation is that data for this analysis were combined from two separate clinical 
trials with different inclusion criteria (SIMPLIFY: injecting drug use in the last six months; 
D3FEAT injecting drug use in the last six months or receiving OAT); however,  D3FEAT 
still recruited a high proportion of people with injecting drug use in the last six months. In 
sensitivity analyses excluding the participants from D3FEAT who did not report injecting in 
the last six months at enrolment, stimulant injecting in the last month and twice-daily therapy 
remained associated with non-adherence. Further, characteristics of the study populations 
were similar, likely due to the use of the same recruitment network for study enrolment, and 
any remaining differences were controlled for in adjusted analyses. Lastly, participants from 
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D3FEAT who were receiving twice-daily therapy represented a less marginalized population, 
despite having poorer adherence.  
 
The results of this study cannot necessarily be generalised to all populations of people who 
inject drugs and people receiving OAT. While the international nature of these data enhances 
the generalisability, participants likely represent a somewhat selected population who were 
engaged with health services and were not co-infected with HIV. Further, participants were 
treated in clinics which may have been more experienced in HCV treatment in these 
populations and the lack of randomisation could have resulted in unmeasured confounding 
due to, for example, the decision by study sites to include/exclude particular patients in the 
trials. 
 
Lastly, adherence to therapy was likely enhanced by weekly contact with healthcare 
providers to return used blister packs and obtain subsequent doses, and the blister pack itself 
may have indirectly acted as an adherence support tool. Furthermore, although the incentive 
received for the return of the blister pack was not linked to the measured adherence, this 
incentive may have indirectly encouraged greater adherence. Despite these limitations, these 
data present a robust analysis of treatment adherence in a high-risk population of people with 
injecting drug use in the last six months and people receiving OAT. 
 
Overall, adherence was high in this study. Different patterns of non-adherence did not impact 
SVR, suggesting a degree of forgiveness to non-adherence with the regimens of once-daily 
sofosbuvir/velpatasvir and twice-daily paritaprevir/ritonavir/ombitasvir, dasabuvir with or 
without ribavirin. Further research is needed to evaluate the impact of adherence on SVR in 
the context of shorter durations of DAA therapy. Taken together, these data support DAA 
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therapy among people with recent injecting drug use and people receiving OAT. These data 
are important to inform clinical guidelines and improve clinical management of HCV 
infection among people with recent injecting drug use. Further, these data provide key 
information to support the removal of restrictions for the reimbursement of HCV DAA 
therapy for people with recent drug/alcohol use that are still in place in some settings globally 
[30, 31].  
  
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciz1089/5611150 by Sandra Angus user on 12 N
ovem
ber 2019
 
19 
 
Acknowledgements 
The authors thank the study participants for their contribution to the research, as well as 
current and past researchers and staff. 
 
Declaration of Interests 
JG reports grants and personal fees from AbbVie, Cepheid, Gilead Sciences, and Merck. OD 
reports grants from Gilead Sciences during this study and grants from Gilead Sciences, 
Merck, and AbbVie, and advisory board fees from Abbvie and MSD. PB reports grants and 
personal fees from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Mundipharma, and 
Merck Sharp & Dohme. MH reports grants from Gilead Sciences, Bristol-Myers Squibb, and 
AbbVie. JBr reports consultant fees from Gilead Sciences and Merck. AHL reports grants 
and personal fees from Gilead Sciences, Merck, and personal fees from Abbvie. GVM reports 
grants and personal fees from Gilead Sciences and grants and personal fees from AbbVie. JP 
reports grants and personal fees from Janssen and Genetech. CC reports grants and personal 
fees from Gilead Sciences, Merck, and Abbvie. JJF reports grants and personal fees from 
AbbVie, Merck, Gilead Sciences, Roche, Wako/Fujifilm, and Janssen, personal fees from 
Contravir, and grants from Abbott and Enanta. CF reports grants and non-financial support 
from Kirby Institute, Abbvie, and Gilead Sciences during this study and grants from Gilead 
Sciences, ViiV HealthCare, Abbvie, and Merck, outside the submitted work. GJD reports 
grants, personal fees, and non-financial support from AbbVie, Merck, Bristol-Myers Squibb, 
and Roche; grants and personal fees from Janssen; personal fees and non-financial support 
from Gilead Sciences; and personal fees from GlaxoSmithKline and Abbott Diagnostics. PR 
reports fees for educational talks from Gilead Sciences, Merck Sharp & Dohme, and AbbVie, 
and is on the advisory board for Merck Sharp & Dohme. BC reports grants, personal fees, 
and non-financial support from Gilead Sciences, Merck, AbbVie, Indivior, and ViiV. EG 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciz1089/5611150 by Sandra Angus user on 12 N
ovem
ber 2019
 
20 
 
reports personal fees from being a Clinical Advisor for Gilead Sciences, Merck, Janssen, and 
AbbVie, and personal fees from Gilead Sciences Speaker Bureau and AbbVie Speaker 
Bureau. JFD reports grants from Abbvie during the course of the study, grants and personal 
fees from Gilead, Merck Sharp & Dohme, Janssen, and AbbVie. BH reports grants from 
AbbVie and Gilead Sciences. DS reports clinical trial nurse support from Kirby Institute, 
during the study. KL reports advisory board fees and travel grants from Abbvie, MSD, and 
Gilead. All other authors declare no competing interests.  
 
 
 
  
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciz1089/5611150 by Sandra Angus user on 12 N
ovem
ber 2019
 
21 
 
References 
[1] Hajarizadeh B, Cunningham EB, Reid H, Law M, Dore GJ, Grebely J. Direct-acting 
antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review 
and meta-analysis. Lancet Gastroenterol Hepatol 2018. 
[2] Barua S, Greenwald R, Grebely J, Dore GJ, Swan T, Taylor LE. Restrictions for 
medicaid reimbursement of sofosbuvir for the treatment of hepatitis c virus infection in the 
united states. Annals of Internal Medicine 2015;163:215-223. 
[3] Marshall AD, Saeed S, Barrett L, Cooper CL, Treloar C, Bruneau J, et al. Restrictions 
for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in 
Canada: a descriptive study. CMAJ Open 2016;4:E605-E614. 
[4] Ooka K, Connolly JJ, Lim JK. Medicaid Reimbursement for Oral Direct Antiviral 
Agents for the Treatment of Chronic Hepatitis C. Am J Gastroenterol 2017;112:828-832. 
[5] Aspinall EJ, Corson S, Doyle JS, Grebely J, Hutchinson SJ, Dore GJ, et al. Treatment 
of Hepatitis C Virus Infection Among People Who Are Actively Injecting Drugs: A 
Systematic Review and Meta-analysis. Clinical Infectious Diseases 2013;57:S80-S89. 
[6] Cunningham EB, Hajarizadeh B, Dalgard O, Amin J, Hellard M, Foster GR, et al. 
Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs 
with hepatitis C virus genotype 2/3 infection: the ACTIVATE study. Bmc Infectious 
Diseases 2017;17. 
[7] Read P, Gilliver R, Kearley J, Lothian R, Cunningham EB, Chronister KJ, et al. 
Treatment Adherence and Support for People who Inject Drugs Taking Direct Acting 
Antiviral Therapy for Hepatitis C Infection. Journal of Viral Hepatitis 2018. 
[8] Cunningham EB, Amin J, Feld JJ, Bruneau J, Dalgard O, Powis J, et al. Adherence to 
sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection 
drug use: The SIMPLIFY study. International Journal of Drug Policy 2018;62:14-23. 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciz1089/5611150 by Sandra Angus user on 12 N
ovem
ber 2019
 
22 
 
[9] Dore GJ, Altice F, Litwin AH, Dalgard O, Gane EJ, Shibolet O, et al. Elbasvir–
Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist 
TherapyA Randomized TrialElbasvir–Grazoprevir in Persons With HCV Receiving OAT. 
Annals of internal medicine 2016;165:625-634. 
[10] Grebely J, Mauss S, Brown A, Bronowicki J-P, Puoti M, Wyles D, et al. Efficacy and 
safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV 
genotype 1 infection receiving opioid substitution therapy: Analysis of Phase 3 ION trials. 
Clinical Infectious Diseases 2016;63:1405-1411. 
[11] Martinello M, Hajarizadeh B, Grebely J, Dore GJ, Matthews GV. HCV Cure and 
Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs. Curr 
Hiv-Aids Rep 2017;14:110-121. 
[12] Lalezari J, Sullivan JG, Varunok P, Galen E, Kowdley KV, Rustgi V, et al. 
Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients 
on methadone or buprenorphine. Journal of Hepatology 2015;63:364-369. 
[13] Grebely J, Dalgard O, Conway B, Cunningham EB, Bruggmann P, Hajarizadeh B, et 
al. Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C viris 
infection and recent injecting drug use: the SIMPLIFY study. The lancet Gastroenterology & 
hepatology 2017. 
[14] Grebely J, Conway B, Cunningham EB, Fraser C, Moriggia A, Gane E, et al. 
Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with 
HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy. 
International Journal of Drug Policy 2018;Accepted. 
[15] Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol 
consumption questions (AUDIT-C): an effective brief screening test for problem drinking. 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciz1089/5611150 by Sandra Angus user on 12 N
ovem
ber 2019
 
23 
 
Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders 
Identification Test. Archives of Internal Medicine 1998;158:1789-1795. 
[16] Bielen R, Moreno C, Van Vlierberghe H, Bourgeois S, Mulkay J-P, Vanwolleghem T, 
et al. Belgian experience with direct acting antivirals in people who inject drugs. Drug and 
Alcohol Dependence 2017;177:214-220. 
[17] Dore G, Altice F, Litwin AH, Dalgard O, Gane EJ, Shibolet O, et al. C-EDGE CO-
STAR: Efficacy of Grazoprevir and Elbasvir in Persons who Inject Drugs (PWID) Receiving 
Opioid Agonist Therapy. Hepatology 2015;62:227a-228a. 
[18] Grebely J, Flamm S, Zeuzem S, Hyland R, Chang P, Ding X, et al. On-Treatment 
Illicit Drug Use Did Not Impact Treatment Outcome during Therapy with Ledipasvir-
Sofosbuvir with or without Ribavirin in the Phase 3 Ion-1 Study. Journal of Hepatology 
2016;64:S776-S777. 
[19] Litwin A, Agyemang L, Akiyama M, Heo M, Wong J, Soloway I, et al. High rates of 
sustained virological response in people who inject drugs treated with all-oral direct acting 
antiviral regimens. 5th International Symposium on Hepatitis Care in Substance Users, Oslo, 
Norway 2016. 
[20] Mason K, Dodd Z, Guyton M, Tookey P, Lettner B, Matelski J, et al. Understanding 
real-world adherence in the directly acting antiviral era: A prospective evaluation of 
adherence among people with a history of drug use at a community-based program in 
Toronto, Canada. International Journal of Drug Policy 2017. 
[21] Petersen T, Townsend K, Gordon LA, Sidharthan S, Silk R, Nelson A, et al. High 
adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient 
population in a phase 2a study. Hepatology International 2016;10:310-319. 
[22] Mbuagbaw L, Sivaramalingam B, Navarro T, Hobson N, Keepanasseril A, 
Wilczynski NJ, et al. Interventions for Enhancing Adherence to Antiretroviral Therapy 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciz1089/5611150 by Sandra Angus user on 12 N
ovem
ber 2019
 
24 
 
(ART): A Systematic Review of High Quality Studies. Aids Patient Care and Stds 
2015;29:248-266. 
[23] Cooper V, Horne R, Gellaitry G, Vrijens B, Lange AC, Fisher M, et al. The Impact of 
Once-Nightly Versus Twice-Daily Dosing and Baseline Beliefs About HAART on 
Adherence to Efavirenz-Based HAART Over 48 Weeks: The NOCTE Study. Jaids-J Acq 
Imm Def 2010;53:369-377. 
[24] Maitland D, Jackson A, Osorio J, Mandalia S, Gazzard BG, Moyle GJ, et al. 
Switching from twice-daily abacavir and lamivudine to the once-daily fixed-dose 
combination tablet of abacavir and lamivudine improves patient adherence and satisfaction 
with therapy. Hiv Medicine 2008;9:667-672. 
[25] Parienti JJ, Bangsberg DR, Verdon R, Gardner EM. Better Adherence with Once-
Daily Antiretroviral Regimens: A Meta-Analysis. Clinical Infectious Diseases 2009;48:484-
488. 
[26] UNODC. World Drug Report 2019. Vienna; 2019. 
[27] Gottfredsson M, Love T, Fridriksdottir RH, Tyrfingsson T, Runarsdottir V, Hansdottir 
I, et al. Is homelessness the biggest hurdle to treatment success in the management of HCV in 
the era of direct acting antivirals? Results from the TraP HepC nationwide treatment initiative 
in Iceland. ILC 2019 -Journal of Hepatology 2019;70:PS-072. 
[28] Aidala AA, Wilson MG, Shubert V, Gogolishvili D, Globerman J, Rueda S, et al. 
Housing Status, Medical Care, and Health Outcomes Among People Living With HIV/AIDS: 
A Systematic Review. American Journal of Public Health 2016;106:95-95. 
[29] Lam WY, Fresco P. Medication Adherence Measures: An Overview. Biomed Res Int 
2015. 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciz1089/5611150 by Sandra Angus user on 12 N
ovem
ber 2019
 
25 
 
[30] Marshall AD, Cunningham EB, Nielsen S, Aghemo A, Alho H, Backmund M, et al. 
Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV 
infection in Europe. Lancet Gastroenterol Hepatol 2018;3:125-133. 
[31] Marshall AD, Pawlotsky JM, Lazarus JV, Aghemo A, Dore GJ, Grebely J. The 
removal of DAA restrictions in Europe - One step closer to eliminating HCV as a major 
public health threat. J Hepatol 2018;69:1188-1196. 
  
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciz1089/5611150 by Sandra Angus user on 12 N
ovem
ber 2019
 
26 
 
 
 Table 1: Participant characteristics at baseline overall and stratified by study 
  
Overall 
(n=190) 
n (%) 
SIMPLIFY  
(once-daily) 
(n=103) 
n (%) 
D3FEAT 
(twice-daily) 
(n=87) 
n (%) 
P 
Age, median (IQR) 48 (41-53) 48 (41-53) 48 (43-54) 0.727 
Male sex 141 (74) 74 (72) 67 (77) 0.417 
High school or greater education 93 (49) 50 (49) 41 (49) 0.971 
Unstable housing 37 (20) 24 (23) 13 (16) 0.195 
Hazardous alcohol consumptiona 97 (51) 18 (17) 10 (12) 0.274 
Opioid substitution treatment (current) 158 (83) 58 (56) 62 (73) 0.018 
OST and recent injecting (past month)  
   
<0.001 
   No OST, no recent injecting 21 (11) 12 (12) 9 (11) 
    No OST, recent injecting 47 (25) 33 (32) 14 (17) 
    OST, no recent injecting 52 (28) 15 (15) 37 (45) 
    OST, recent injecting 68 (36) 43 (42) 23 (28) 
 Study site distribution 
   
0.003 
   Australia/New Zealand 61 (32) 43 (42) 18 (21) 
    North America 78 (41) 40 (39) 38 (44) 
    Europe 51 (27) 20 (19) 31 (36) 
 Any injecting drug use in the last month 115 (61) 76 (74) 39 (46) <0.001 
Injecting drug use >daily in the last monthb 40 (35) 27 (36) 13 (33) 0.815 
Drugs injected in the last monthb 
       Heroin 77 (67) 55 (72) 22 (59) 0.167 
   Cocaine 21 (18) 12 (16) 9 (24) 0.274 
   Amphetamines 42 (37) 27 (36) 15 (41) 0.605 
a According to AUDIT-C with hazardous alcohol consumption defined as a score of ≥3 in women and 
≥4 in men 
b Among those who reported injecting in the last month.  
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Table 2: Measures of treatment completion and adherence stratified by dosing pattern. 
Variable 
Overall 
(n=190) 
n (%) 
Once-daily 
(n=103) 
n (%) 
Twice-daily 
(n=87) 
n (%) 
Treatment completion 184 (97) 100 (97) 84 (97) 
Number of days non-adherent to therapy, 
n (%)    
    None (100% adherent) 19 (10) 12 (12) 7 (8) 
    1-4 (95-<100% adherent) 56 (29) 36 (35) 20 (23) 
    5-8 (90-<95% adherent) 35 (18) 20 (19) 15 (17) 
    9-17 (80-<90% adherent) 34 (18) 17 (17) 17 (20) 
    ≥18 (<80% adherent) 46 (24) 18 (17) 28 (32) 
Overall adherence (% [95% CI]) 
   
    Patient report 99 (97-100) 99 (98-100) 99 (96-100) 
    Blister pack, weekly 98 (94-100) 98 (94-100) 98 (93-99) 
    Blister pack, daily 92 (81-98) 94 (88-98) 88 (75-96) 
Longest episode of non-adherence (days) 
      1 80 (42) 44 (43) 36 (41) 
   2 39 (21) 19 (18) 20 (23) 
   3 8 (4) 3 (3) 5 (6) 
   4 11 (6) 9 (9) 2 (2) 
   5 5 (3) 2 (2) 3 (3) 
   6 3 (2) 3 (3) 0 (0) 
   ≥7 25 (13) 11 (11) 14 (16) 
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Table 3: Logistic regression of factors associated with nonadherence (<90%) 
  
DAA 
adherence of 
≥90% (%; 
n=114) 
DAA adherence 
of <90% (%; 
n=76) 
Unadjusted OR  P Adjusted OR  P 
Age (years) 
     
   <48 53 (55) 44 (45) 1.00 - 
  
   >48 61 (66) 32 (34) 0.63 (0.35-1.13) 0.124 
  
Gender 
      
    Male 81 (57) 60 (43) 1.00 - 
  
   Female 33 (67) 16 (33) 0.65 (0.33-1.30) 0.225 
  
Education 
     
   <High school 60 (63) 36 (38) 1.00 - 
  
   High school or 
greater 
53 (58) 38 (42) 0.97 (0.85-1.10) 0.606 
  
Housing 
      
   Stable 96 (64) 53 (36) 1.00 
   
   Unstable 17 (46) 20 (54) 2.13 (1.03-4.41) 0.042 2.18 (1.01-4.70) 0.046 
Hazardous alcohol consumption 
    
   No 95 (59) 65 (41) 1.00 - 
  
   Yes 19 (68) 9 (32) 0.69 (0.29-1.63) 0.398 
  
Current OAT 
     
   No 44 (65) 24 (35) 1.00 - 
  
   Yes 69 (58) 51 (43) 1.36 (0.73-2.51) 0.333 
  
Injecting (last month)a 
     
   No 51 (70) 22 (30) 1.00 - 
  
   Yes 63 (55) 52 (45) 1.91 (1.03-3.56) 0.040 
  
Frequency of injecting (last month)a 
    
   Never 51 (70) 22 (30) 1.00 - 
  
   Less than daily 40 (53) 35 (47) 2.03 (1.03-3.98) 0.040 
  
   Daily or greater 23 (58) 17 (43) 1.71 (0.77-3.82) 0.188 
  
Any injecting during treatment 
    
   No 42 (68) 20 (32) 1.00 - 
  
   Yes 72 (58) 52 (42) 1.52 (0.80-2.88) 0.203 
  
Heroin injecting (last month) 
    
   No 65 (61) 41 (39) 1.00 - 
  
   Yes 48 (59) 34 (41) 1.12 (0.62-2.02) 0.699 
  
Cocaine injecting (last month) 
    
   No 102 (62) 62 (38) 1.00 - 
  
   Yes 11 (50) 11 (50) 1.65 (0.67-4.02) 0.275 
  
Amphetamine injecting (last month) 
   
   No 92 (66) 48 (34) 1.00 - 
  
   Yes 21 (46) 25 (54) 2.28 (1.16-4.49) 0.017 
  
Cocaine/amphetamine injecting (last month) 
   
   No 82 (66) 42 (34) 1.00 - 
     Yes 31 (48) 33 (52) 2.08 (1.12-3.85) 0.020 2.48 (1.28-4.82) 0.007 
Fibrosis stage 
   
     F0-F1 77 (61) 50 (39) 1.00 - 
     F2-F3 23 (59) 16 (41) 1.07 (0.52-2.22) 0.853 
     F4 10 (59) 7 (41) 1.08 (0.39-3.02) 0.886 
  
Dosing pattern 
   
     Once-daily 71 (69) 32 (31) 1.00 - 
     Twice-daily 43 (49) 44 (51) 2.27 (1.26-4.11) 0.007 2.81 (1.47-5.36) 0.002 
a Not included in adjusted analysis due to collinearity with drug type. 
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FIGURE LEGENDS 
 
Figure 1: OAT and injecting status of participants from SIMPLIFY (blue) and D3FEAT (orange) at 
enrolment. 
 
Figure 2: Blister packs used for dosing and adherence monitoring in DEFEAT (A) and SIMPLIFY 
(B). 
 
Figure 3: Daily adherence to therapy in SIMPLIFY (top) and D3FEAT (bottom) measured by weekly 
administered electronic blister packs. Each row represents an individual patient and each column 
represents one day of therapy. Dark blue boxes represent 100% of prescribed doses received, mid-
blue represents 50% of daily doses received (in D3FEAT only) and light blue boxes represent no dose 
received. White boxes represent early discontinuation of treatment. Failure to achieve SVR due to 
virologic failure (red), reinfection (yellow), loss to follow-up (grey), and death (black) is denoted on 
the right. 
 
Figure 4: Violin plot of adherence to HCV DAA treatment among people receiving once-daily 
therapy (blue) and twice-daily therapy (orange). 
 
Figure 5: Mean daily adherence over the course of therapy among those receiving once-daily (blue) 
and twice-daily (orange) dosing. 
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Figure 1. 
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Figure 2. 
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Figure 3. 
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Figure 4. 
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Figure 5. 
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